Poziotinib Shows Promise for Treating Patients with NSCLC and EGFR or HER2 Exon 20 Insertion Mutations

2020 Year in Review - Non–Small-Cell Lung Cancer - Lung Cancer

This study reports on the ZENITH20-2 cohort of previously treated patients with advanced NSCLC and an HER2 exon 20 insertion mutation.

ZENITH20 is a multicohort phase 2 study of poziotinib, a potent EGFR and HER2 exon 20 tyrosine kinase inhibitor (TKI) for the treatment of non–small-cell lung cancer (NSCLC). ZENITH20-2 targeted patients who had HER2 exon 20 insertion mutations as determined by a Clinical Laboratory Improvement Amendments–certified or equivalent sequencing test. Patients were given an oral dose of 16 mg of poziotinib daily, with allowances for changes or interruptions of treatment because of toxicity. A central independent image review committee (IIRC) evaluated the objective response rate (ORR) as a primary end point according to Response Evaluation Criteria in Solid Tumours 1.1 guidelines, with a 95% confidence interval (CI) prespecified lower bound of 17%. Disease control rate (DCR), duration of response (DOR), progression-free survival (PFS), and safety were secondary end points.

ZENITH20-2 enrolled 90 patients with advanced NSCLC and an HER2 exon 20 insertion mutation. The cohort had a median age of 60 years, was 64% female, 66% nonsmokers, 78% Caucasians, and 16% had concurrent clinically stable brain metastases at entry. Patients had a median of 2 prior therapies (range, 1-6); 98% had prior chemotherapy/platinum-based therapy, 67% had immunotherapy (including checkpoint inhibitors), and 28% had HER2 therapy.

The ORR in all 90 patients was 27.8% (95% CI, 18.9%-38.2%) and was 35.1% (95% CI, 24.4%-47.1%) in 74 patients who were evaluated by the IIRC. The DCR was 70%, the median PFS was 5.5 months (range, 0.03-13.1+ months), and the median DOR was 5.1 months (range, 1-12.3+ months, with 3 patients continuing treatment). Most subgroups showed a response to poziotinib; 31 patients with ≥3 treatments had an ORR of 38.7%, and 14 patients with central nervous system metastasis had an ORR of 28.6%. Rash (30%), diarrhea (26%), and mucosal inflammation (14%) were the most common adverse events of grade ≥3.

The ZENITH20-2 phase 2 clinical trial exceeded the designated 95% CI lower bound threshold of 17% for the ORR primary end point. The authors noted that the promising responses and manageable safety profile were typical of second-generation TKIs. Further studies will focus on alternative dosing strategies.

Reference
Socinski MA, et al. ESMO 2020. Abstract LBA60.

Related Items
Antibody–Drug Conjugate Shows Promising Activity in Patients with Advanced or Metastatic EGFR Mutation–Positive NSCLC
Patricia Stewart
TOP - January 2022 Vol 15, No 1 – Online Only published on January 20, 2022 in Lung Cancer
Amivantamab plus Lazertinib Combo Improves Response in Osimertinib-Resistant EGFR-Positive NSCLC
Patricia Stewart
TOP - November 2021 Vol 14, No 7 published on November 10, 2021 in Lung Cancer
Sotorasib Shows Encouraging Activity in Patients with NSCLC and KRAS p.G12C Mutation
Patricia Stewart
TOP - September 2021 Vol 14, No 5 published on September 7, 2021 in Lung Cancer
Neoadjuvant Nivolumab plus Chemotherapy Significantly Improves Pathologic Complete Response in Patients with Resectable NSCLC
Patricia Stewart
TOP - September 2021 Vol 14, No 5 published on September 7, 2021 in Lung Cancer
Educating NSCLC Patients on Adverse Event Management
Kammi Fox-Kay, MSN, RN, AOCNS, ONN-CG(T), Cathy Simmons, RN, BSN, ONN-CG(T), Lauren Welch, MSN, NP-C, AOCNP
Videos published on July 8, 2021 in Interview with the Innovators, Lung Cancer, Adverse Events
Addressing Lung Cancer Screening Disparities in LGBT Populations
William Ackerman
TOP - May 2021 Vol 14, No 3 published on May 14, 2021 in Lung Cancer
Analysis Identifies EGFR as Most Common Mutation in Women with Lung Cancer and No Smoking History
William Ackerman
TOP - May 2021 Vol 14, No 3 published on May 14, 2021 in Lung Cancer
Cemiplimab Potential New Treatment Option for Patients with Advanced NSCLC and PD-L1 ≥50%
Patricia Stewart
TOP - January 2021 Vol 14, No 1 published on February 9, 2021 in Lung Cancer
“Astonishing Results” Seen with First-Line Lorlatinib for the Treatment of ALK-Positive NSCLC
Patricia Stewart
TOP - January 2021 Vol 14, No 1 published on February 9, 2021 in Lung Cancer
Patients with BRAF V600E–Mutant NSCLC Show Improved Overall Survival with Dabrafenib + Trametinib Combination
2020 Year in Review - Non–Small-Cell Lung Cancer published on January 29, 2021 in Lung Cancer
Last modified: July 22, 2021